95 related articles for article (PubMed ID: 16433042)
1. Effect of SILA-409, a new organosilicon multidrug resistance modifier, on human pancreatic cancer xenografts.
Zalatnai A; Molnár J
In Vivo; 2006; 20(1):137-40. PubMed ID: 16433042
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
3. Establishment and serial quantification of intrahepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance.
Leveille-Webster CR; Arias IA
Clin Cancer Res; 1996 Apr; 2(4):695-706. PubMed ID: 9816220
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
5. Short-term octreotide treatment induces apoptosis in human pancreatic cancer xenografts.
Zalatnai A; Bocsi J
In Vivo; 2006; 20(4):549-52. PubMed ID: 16900788
[TBL] [Abstract][Full Text] [Related]
6. In vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells.
Gyémánt N; Tanaka M; Antus S; Hohmann J; Csuka O; Mándoky L; Molnár J
In Vivo; 2005; 19(2):367-74. PubMed ID: 15796199
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis-induction and phosphorylation state in human pancreatic carcinoma xenografts following octreotide treatment.
Zalatnai A; Pogány V
Anticancer Res; 2001; 21(1A):477-80. PubMed ID: 11299782
[TBL] [Abstract][Full Text] [Related]
8. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
[TBL] [Abstract][Full Text] [Related]
9. Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells.
Limtrakul P; Siwanon S; Yodkeeree S; Duangrat C
Phytomedicine; 2007 Jun; 14(6):381-9. PubMed ID: 17467965
[TBL] [Abstract][Full Text] [Related]
10. Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine.
Liang GW; Lu WL; Wu JW; Zhao JH; Hong HY; Long C; Li T; Zhang YT; Zhang H; Wang JC; Zhang X; Zhang Q
Fundam Clin Pharmacol; 2008 Aug; 22(4):429-37. PubMed ID: 18705753
[TBL] [Abstract][Full Text] [Related]
11. Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells.
Mansilla S; Rojas M; Bataller M; Priebe W; Portugal J
Biochem Pharmacol; 2007 Apr; 73(7):934-42. PubMed ID: 17217917
[TBL] [Abstract][Full Text] [Related]
12. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
[TBL] [Abstract][Full Text] [Related]
13. Enhanced potency of daunorubicin against multidrug resistant subline KB-ChR-8-5-11 by a pulsed magnetic field.
Liang Y; Hannan CJ; Chang BK; Schoenlein PV
Anticancer Res; 1997; 17(3C):2083-8. PubMed ID: 9216668
[TBL] [Abstract][Full Text] [Related]
14. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
15. STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model.
Gao L; Chen L; Fei XH; Qiu HY; Zhou H; Wang JM
Chin Med J (Engl); 2006 Jun; 119(11):911-8. PubMed ID: 16780770
[TBL] [Abstract][Full Text] [Related]
16. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric evidence of apoptosis in human pancreatic cancer xenografts treated with Sandostatin (octreotide).
Zalatnai A; Szegedi Z; Bocsi J
Anticancer Res; 2000; 20(3A):1663-6. PubMed ID: 10928088
[TBL] [Abstract][Full Text] [Related]
18. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
19. Antineoplastic activity of 2-methoxyestradiol in human pancreatic and gastric cancer cells with different multidrug-resistant phenotypes.
Schumacher G; Hoffmann J; Cramer T; Spinelli A; Jacob D; Bahra M; Pratschke J; Pfitzmann R; Schmidt S; Lage H
J Gastroenterol Hepatol; 2007 Sep; 22(9):1469-73. PubMed ID: 17645459
[TBL] [Abstract][Full Text] [Related]
20. Anticancer effects of the organosilicon multidrug resistance modulator SILA 421.
Olszewski U; Zeillinger R; Kars MD; Zalatnai A; Molnar J; Hamilton G
Anticancer Agents Med Chem; 2012 Jul; 12(6):663-71. PubMed ID: 22263791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
